Daniel Chin, Tamara Hernández-Beeftink, Lauren J. Donoghue, Beatriz Guillén‐Guío, Olivia C. Leavy, Ayodeji Adegunsoye, Helen Booth, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, William A. Fahy, Tasha E. Fingerlin, Bibek Gooptu, Ian P. Hall, Simon P. Hart, Mike Hill, Nik Hirani, Simon R. Johnson, Naftali Kaminski, José M. Lorenzo-Salazar, Shwu‐Fan Ma, Robin J. McAnulty, Mark I. McCarthy, Amy Stockwell, Toby M. Maher, Ann Millar, Philip L. Molyneaux, María Molina‐Molina, Vidya Navaratnam, Margaret Neighbors, Justin M. Oldham, Helen Parfrey, Gauri Saini, Ian Sayers, X Rebecca Sheng, Iain Stewart, Mary E. Strek, Martin D. Tobin, Moira K. B. Whyte, Maria C. Zarcone, Yingze Zhang, Fernando J. Martínez, Brian L. Yaspan, Carl Reynolds, David A. Schwartz, Carlos Flores, Imre Noth, Gísli Jenkins, Richard J. Allen, Louise V. Wain
Extract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease thought to result from an aberrant response to lung injury, culminating in an exaggerated healing response with excessive deposition of extracellular matrix in the interstitium [1].